1. Generics Bulletin
  2. >>Products

‘Middlemen’ Markups Are Penalizing Patients, Says AAM

Cash Prices For Generic Drugs Are Substantially Higher Than Manufacturer Prices

 
• By Chloe Kent

The Association for Accessible Medicines has launched its Markup Madness campaign, which seeks to draw attention to the disparity in cost between generic drugs upon entry to the supply chain and when purchased in pharmacies.

Infographic showing atorvastatin markup
AAM says generics manufacturers do not have the same control over their supply chain as branded drugs • Source: Association For Accessible Medicines

Patients in the US are paying steep cash markups on generic drugs due to costs charged by supply-chain middlemen, says the Association for Accessible Medicines.

The trade group, which represents the manufacturers and distributors of generic prescription drugs, has launched the Markup Madness campaign to highlight this issue, which it says means “patients are paying too much” for their medication

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Viatris Pens Aprepitant Settlement Agreement After Kabi Loses Initial Patent Case

 
• By Dean Rudge

Viatris will look to introduce generic versions of Heron Therapeutics’ aprepitant brands, Cinvanti and Aponvie, around three years before patent expiry after settling litigation with the originator. Other court cases remain ongoing.